Tatva Chintan Pharma accepts Ajay Rawat resignation as R&D head
Tatva Chintan Pharma Chem Ltd announced the acceptance of Mr. Ajay Rawat’s resignation as Assistant Vice President – Research and Development. Effective November 13, 2026, Mr. Rawat will cease to be part of the senior management team after submitting his resignation on August 14, 2026. The move was disclosed under Regulation 30 of SEBI Listing Regulations.

*this image is generated using AI for illustrative purposes only.
Tatva Chintan Pharma Chem Limited has accepted the resignation of Mr. Ajay Rawat, who served as Assistant Vice President – Research and Development. The company disclosed that Mr. Rawat submitted his resignation letter on August 14, 2026, citing personal career opportunities as the reason for his departure.
The management formally accepted the resignation on August 19, 2026. Mr. Rawat’s exit will become effective from the close of business hours on November 13, 2026. During this transition period, he will continue to perform his duties as a Senior Management Personnel of the company.
Regulatory Disclosure
The intimation was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also references SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, which was issued on July 11, 2023, and last updated on January 30, 2026.
| Particulars | Details |
|---|---|
| Resigning Executive | Mr. Ajay Rawat |
| Designation | Assistant Vice President – Research and Development |
| Resignation Date | August 14, 2026 |
| Acceptance Date | August 19, 2026 |
| Effective Date | November 13, 2026 |
The complete disclosure, including Annexure A and a copy of the resignation letter, is available on the company’s website at www.tatvachintan.com . Ishwar Nayi, Company Secretary and Compliance Officer, signed the communication to the stock exchanges.
Historical Stock Returns for Tatva Chintan Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.31% | -7.71% | -3.85% | +37.35% | +52.66% | -25.19% |
How will Tatva Chintan Pharma Chem plan to fill the Assistant Vice President – R&D role to ensure continuity in its pipeline development?
Does Mr. Rawat's departure signal a broader shift in the company's research strategy or potential restructuring within the R&D department?
What impact might this leadership change have on the timeline for upcoming clinical trials or product launches currently under his supervision?


































